Ultragenyx Pharmaceutical announced record revenue for its second quarter, surpassing analyst expectations on both revenue and earnings per share. The company reaffirmed its full-year 2026 financial guidance, citing strong performance from its key products.
Key Highlights
- Second quarter total revenue reached a company record of $214 million, a significant beat compared to the $182.5 million consensus estimate.
- Net loss per share was $0.90, which was narrower than the anticipated loss of $1.27 per share.
- Crysvita, the company's leading product, generated revenue of $156 million for the quarter, exceeding investor expectations.
- Ultragenyx reaffirmed its full-year 2026 total revenue guidance of $730 million to $760 million, excluding potential new product launches.